Expanding Arsenal against Neurodegenerative Diseases Using Quercetin Based Nanoformulations : Breakthroughs and Bottlenecks
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Quercetin (Qu), a dietary flavonoid, is obtained from many fruits and vegetables such as coriander, broccoli, capers, asparagus, onion, figs, radish leaves, cranberry, walnuts, and citrus fruits. It has proven its role as a nutraceutical owing to numerous pharmacological effects against various diseases in preclinical studies. Despite these facts, Qu and its nanoparticles are less explored in clinical research as a nutraceutical. The present review covers various neuroprotective actions of Qu against various neurodegenerative diseases (NDs) such as Alzheimer's, Parkinson's, Huntington's, and Amyotrophic lateral sclerosis. A literature search was conducted to systematically review the various mechanistic pathways through which Qu elicits its neuroprotective actions and the challenges associated with raw Qu that compromise therapeutic efficacy. The nanoformulations developed to enhance Qu's therapeutic efficacy are also covered. Various ongoing/completed clinical trials related to Qu in treating various diseases, including NDs, are also tabulated. Despite these many successes, the exploration of research on Qu-loaded nanoformulations is limited mostly to preclinical studies, probably due to poor drug loading and stability of the formulation, time-consuming steps involved in the formulation, and their poor scale-up capacity. Hence, future efforts are required in this area to reach Qu nanoformulations to the clinical level.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Current neuropharmacology - 21(2023), 7 vom: 01., Seite 1558-1574 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vishwas, Sukriti [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9IKM0I5T1E |
|---|
| Anmerkungen: |
Date Completed 22.05.2023 Date Revised 19.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1570159X20666220810105421 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34469593X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34469593X | ||
| 003 | DE-627 | ||
| 005 | 20231226023354.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1570159X20666220810105421 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM34469593X | ||
| 035 | |a (NLM)35950245 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vishwas, Sukriti |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expanding Arsenal against Neurodegenerative Diseases Using Quercetin Based Nanoformulations |b Breakthroughs and Bottlenecks |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.05.2023 | ||
| 500 | |a Date Revised 19.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Quercetin (Qu), a dietary flavonoid, is obtained from many fruits and vegetables such as coriander, broccoli, capers, asparagus, onion, figs, radish leaves, cranberry, walnuts, and citrus fruits. It has proven its role as a nutraceutical owing to numerous pharmacological effects against various diseases in preclinical studies. Despite these facts, Qu and its nanoparticles are less explored in clinical research as a nutraceutical. The present review covers various neuroprotective actions of Qu against various neurodegenerative diseases (NDs) such as Alzheimer's, Parkinson's, Huntington's, and Amyotrophic lateral sclerosis. A literature search was conducted to systematically review the various mechanistic pathways through which Qu elicits its neuroprotective actions and the challenges associated with raw Qu that compromise therapeutic efficacy. The nanoformulations developed to enhance Qu's therapeutic efficacy are also covered. Various ongoing/completed clinical trials related to Qu in treating various diseases, including NDs, are also tabulated. Despite these many successes, the exploration of research on Qu-loaded nanoformulations is limited mostly to preclinical studies, probably due to poor drug loading and stability of the formulation, time-consuming steps involved in the formulation, and their poor scale-up capacity. Hence, future efforts are required in this area to reach Qu nanoformulations to the clinical level | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a Quercetin | |
| 650 | 4 | |a antioxidant | |
| 650 | 4 | |a neurodegenerative disease | |
| 650 | 4 | |a neuroinflammation | |
| 650 | 4 | |a novel drug delivery systems | |
| 650 | 7 | |a Quercetin |2 NLM | |
| 650 | 7 | |a 9IKM0I5T1E |2 NLM | |
| 700 | 1 | |a Kumar, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Khursheed, Rubiya |e verfasserin |4 aut | |
| 700 | 1 | |a Ramanunny, Arya Kadukkattil |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Rajan |e verfasserin |4 aut | |
| 700 | 1 | |a Awasthi, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Corrie, Leander |e verfasserin |4 aut | |
| 700 | 1 | |a Porwal, Omji |e verfasserin |4 aut | |
| 700 | 1 | |a Arshad, Mohammed F |e verfasserin |4 aut | |
| 700 | 1 | |a Alshammari, Mohammed Kanan |e verfasserin |4 aut | |
| 700 | 1 | |a Alghitran, Abdulrahman A |e verfasserin |4 aut | |
| 700 | 1 | |a Qumayri, Ashwaq N |e verfasserin |4 aut | |
| 700 | 1 | |a Alkhaldi, Saif M |e verfasserin |4 aut | |
| 700 | 1 | |a Alshammari, Abdulaziz Khalaf |e verfasserin |4 aut | |
| 700 | 1 | |a Chellappan, Dinesh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Gaurav |e verfasserin |4 aut | |
| 700 | 1 | |a Collet, Trudi |e verfasserin |4 aut | |
| 700 | 1 | |a Adams, Jon |e verfasserin |4 aut | |
| 700 | 1 | |a Dua, Kamal |e verfasserin |4 aut | |
| 700 | 1 | |a Gulati, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sachin Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current neuropharmacology |d 2004 |g 21(2023), 7 vom: 01., Seite 1558-1574 |w (DE-627)NLM175794456 |x 1875-6190 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:7 |g day:01 |g pages:1558-1574 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1570159X20666220810105421 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 7 |b 01 |h 1558-1574 | ||